Skip to main content
CADL logo

Candel Therapeutics, Inc. (CADL)

CADLNASDAQHealthcareBiotechnology

$5.04Today:−$0.19 (−3.57%)1Y +12.75%

As of Nov 20, 2026 close

Market cap
$396.99M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$4.35$14.00
Volume (live)
-
Avg. volume (3M)
1.44M

Candel Therapeutics (CADL) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Candel Therapeutics reported total assets of $125.19M and total liabilities of $73.27M. Shareholders' equity was $51.92M, down 21.7% from $66.33M a year earlier. Total debt stood at $47.58M against $119.73M in cash and short-term investments, a net cash position of $72.16M. That puts debt-to-equity at 0.92, compared with 0.19 a year earlier.

Candel Therapeutics Balance Sheet Analysis

Values in millions USD

Scroll to see more
Balance sheet showing assets, liabilities, and shareholders' equity for Candel Therapeutics, Inc. (CADL) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Current Assets
Cash and Cash Equivalents119.73102.6535.4170.0682.6435.055.18
Short-Term Investments0.000.000.000.000.000.0039.88
Cash & Short-Term Investments119.73102.6535.4170.0682.6435.0545.06
Accounts Receivable0.000.000.000.000.000.000.00
Inventory0.000.000.000.000.000.000.00
Other Current Assets1.661.151.381.892.300.090.15
Total Current Assets121.39103.8036.8071.9584.9535.1545.21
Non-Current Assets
Property, Plant & Equipment (Net)3.302.734.025.483.842.790.43
Long-Term Investments0.420.000.000.270.420.000.27
Other Non-Current Assets0.500.330.380.000.420.350.00
Total Non-Current Assets3.813.064.406.574.263.140.69
Total Assets125.20106.8741.2078.5289.2138.2845.90
Current Liabilities
Accounts Payable1.130.240.420.381.590.920.22
Short-Term Debt0.459.908.890.460.000.460.00
Current Portion of Long-Term Debt-9.908.89----
Accrued Liabilities7.334.723.964.723.443.14-
Other Current Liabilities0.0922.110.404.770.330.191.19
Total Current Liabilities9.0037.5314.185.625.364.711.41
Non-Current Liabilities
Long-Term Debt47.132.6012.3822.340.560.480.42
Deferred Tax Liabilities0.000.000.000.830.000.000.00
Other Non-Current Liabilities15.600.000.921.8819.157.4651.86
Total Non-Current Liabilities64.283.0114.2725.1919.7157.1352.53
Total Liabilities73.2740.5428.4630.8125.0712.7853.94
Stockholders' Equity
Common Stock0.550.470.290.290.290.120.12
Retained Earnings-230.39-192.21-137.03-99.09-80.30-44.17-26.49
Accumulated Other Comprehensive Income0.00-0.000.00-89.210.00-0.02
Treasury Stock0.450.450.450.45---
Additional Paid-in Capital282.21258.51149.48146.51144.1520.49-30.70
Shares Outstanding54.9046.8129.0928.9228.69--
Total Stockholders' Equity51.9266.3312.7547.7164.1425.50-8.04
Total Liabilities & Equity125.20106.8741.2078.5289.2138.2845.90

Source: Company financial statements from annual and quarterly filings. Data as of Sep 30, 2026. Data sources and methodology

Frequently Asked Questions About Candel Therapeutics Balance Sheet

How much debt does Candel Therapeutics have?

Candel Therapeutics had total debt of $47.58M as of Dec 31, 2025, against $119.73M in cash and short-term investments. Its debt-to-equity ratio was 0.92. Total debt was $12.50M a year earlier.

What are Candel Therapeutics' total assets?

Candel Therapeutics reported total assets of $125.19M as of Dec 31, 2025, up 17.2% from $106.87M a year earlier. Total liabilities were $73.27M.

What is Candel Therapeutics' shareholders' equity?

Candel Therapeutics' shareholders' equity was $51.92M as of Dec 31, 2025, or about $0.95 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition